Pfizer Says Research and Development Head John LaMattina Will Retire This Year
Company to Focus on Accelerating Development and Commercialization of Strong Early- and Mid-Stage Pipeline
"Science is at the heart of Pfizer, where world-class scientists use cutting-edge technologies to find new cures for diseases that cut short far too many lives," said Jeff Kindler, Pfizer's Chairman and Chief Executive Officer. "Pfizer now has a significant array of early- and mid-stage product candidates across a range of important therapeutic areas, and John has made a critical contribution to building this foundation. With that in place, John felt it was the right time to retire as we look to the future and accelerate the development of our most promising compounds so that they will be ready for commercialization as rapidly as possible."
Pfizer's research now includes 249 total programs with new therapies in development for obesity, diabetes, rheumatoid arthritis, schizophrenia, oncology, liver disease, HIV and Alzheimer's disease, among others. To further enhance the productivity of the R&D organization, Pfizer announced a series of initiatives at its January 22 analyst meeting, including site consolidations. There continues to be good progress on executing these plans, with, for example, a high rate of acceptance by Ann Arbor colleagues who have been offered the opportunity to relocate to other Pfizer R&D sites.
Pfizer also announced that, after a distinguished career in which he made important contributions, Chief Financial Officer Alan Levin has resigned to pursue career opportunities outside Pfizer.
Most read news
Topics
Organizations
Other news from the department people
Get the chemical industry in your inbox
From now on, don't miss a thing: Our newsletter for the chemical industry, analytics, lab technology and process engineering brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.